US FDA and NIH cuts are expected to delay drug approvals and decrease grant funding, making it harder for young health sector companies to survive.

Tobias Egle has left his role working for the tech and biotech venture fund M Ventures after three years at the CVC.

Origgi is joining Valo Therapeutics as CEO after four years at investment unit Johnson and Johnson Innovation,

The hire is part of its goal to strengthen its presence in the biotech sector and expand its international investment platform.

The launch of the fund follows Sanofi’s investment in a $1bn insulin production facility in Beijing, China.

UK universities have also reduced their average equity stakes to new a new low.

Shaw was vice president of M&A at Synchrony Ventures before working in institutional VC.

Corporate investors have become pivotal players in VC markets around the globe, able to move markets. It’s now time to press our advantage.

Anchor investor Shanghai Industrial Investment targets opportunities in biomedical sectors, including neurodegeneration and gene therapy.

Hospital CVCs are growing and diversifying to confront the challenges facing the US healthcare system.